Texas Oncology, P.A

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma3 trials
• Colorectal cancer2 trials
• Gastric and oesophageal cancer2 trials
• Endometrial cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Neuroendocrine tumours1 trial
• Sarcoma1 trial
• Thyroid cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 35 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 21 trial

Status

• Completed4 trials
• Terminated2 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC2 trials
• BioNTech SE1 trial
• G1 Therapeutics, Inc.1 trial
• Hutchmed1 trial
• Inspirna, Inc.1 trial
• and 2 more

Running trials

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· BioNTech SE· Source

• Active, not recruiting

  Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

  NCT04782687· Phase 2· US Oncology Research· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer1 recruiting

Closed trials

• Terminated

  Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

  NCT05065411· Phase 3· Veru Inc.· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source

• Terminated

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· Phase 1/2· Hutchmed· Source

• Completed

  A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  NCT03901963· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

  NCT03597581· Phase 1· Inspirna, Inc.· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Janssen Research & Development, LLC· Source